What are the current standards of care and recent developments in the management of breast cancer?

Oncologist

Volumn 11, Issue SUPPL. 1, 2006, Pages 1-3

  Cameron, David ^a   Bell, Richard ^b   Aapro, Matti ^c   Zielinski, Christoph ^d  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b Andrew Love Cancer Centre   (Australia)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; GEMCITABINE; IBANDRONIC ACID; NAVELBINE; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ALOPECIA; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; PATIENT CARE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; EDITORIAL; FEMALE; STANDARD;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS; FEMALE; HUMANS; PATIENT CARE MANAGEMENT;

EID: 39049192124     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-90001-1     Document Type: Conference Paper

References (28)

1. Aapro MS. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th International Conference, St. Gallen, February 2001. The Oncologist 2001;6:376-385.
2. Coleman RE. Current and future status of adjuvant therapy for breast cancer. Cancer 2003;97(suppl):880-886.
3. Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-2313.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-1672.
5. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-1684.
6. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005;94(suppl 1):S5.
7. Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809-820.
8. The HERA Study Team. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer (HERA trial): disease-free and overall survival after 2 year median follow-up. Slide presentation at the 42nd American Society of Clinical Oncology Annual Meeting, Atlanta, GA, June 2-6, 2006.
9. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pre-treated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812-2823.
10. Beslija S, Obralic N, Basic H et al. A single institution randomized trial of Taxotere (T) and Xeloda (X) given in combination vs. Taxotere (t) followed by Xeloda (x) after progression as first line chemotherapy (CT) for metastatic breast cancer(MBC). EJC Suppl 2005;3:114.
11. Blum JL, Jones SE, Buzdar AU et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-493.
12. Powles T, Paterson A, McCloskey E et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer[ISRCTN83688026]. Breast Cancer Res 2006;8:R13. Epub 2006 Mar l5.
13. Bernard-Marty C, Cardoso F, Pic cart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. The Oncologist 2004;9:617-632.
14. Marty M, Cognetti F, Maraninchi D et al. Randomized phase IItrial of the efficacy and safety of trastuzum abcombined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M 77001 study group. J Clin Oncol 2005;23;4265-4274.
15. Slamon DJ, Leyland-Jones B, Shak Setal, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2, N Engl J Med 2001;344:783-792.
16. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001;12:1247-1254.
17. Talbot DC, Moiseyenko V, Van Belle S et al, Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advance d breast cancer pretreated with anthracyclines. Br J Cancer 2002;86:1367-1372.
18. ReynosoN, Torrecillas L, Soto Cet al. Economic evaluation of sequential capecitabine (X) and taxanes vs. the combinations in patients (pts) with advanced/metastatic breast cancer(MBC): a Mexican Oncology Study Group (MOSG) Trial. Breast Cancer Res Treat 2005;94 (suppl 1):S219.
19. Batista N, Perez-Manga G, Constenla M et al. Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer. Br J Cancer 2004;90:1740-1746.
20. Gradishar WJ, Meza LA, Am in D et al. Capecitabine plus paclitaxel as front-line combination therapy for metastatic breast cancer: a multicenter phase II study. J Clin Oncol 2004;22:2321-2327.
21. Welt A, von Minckwitz G, Oberhoff C et al. Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer. Ann Oncol 2005;16:64-69.
22. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-799.
23. Perez EA. Metastatic bone disease in breast cancer: the patient's perspective. Semin Oncol 2001;28(suppl 11):60-63.
24. Body J-J, DielI J, Lichinitser M R et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14:1399-1405.
25. Body J-J, DielIJ, Bell R et al. Oral ibandronate improves bonepain and preserves quality of life in patients with skeletal metastases due to breast cancer, Pain 2004;111:306-312.
26. Body J-J, DielIJ, Lichinitzer M et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer pat tients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer 2004;90:l133-1137.
27. Diel IJ, Body J-J, Lichinitser M R et al. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004 ;40:1704-1712.
28. Heidenreich A, Ohlmann C, Olbert Pet al. High-dose ibandronate is effective and well tolerated in the treatment of pain and hypercalcaemia due to metastatic urologic cancer, EJC Suppl 2003;1:S270.